PDF
ePub
Citation
Print
Abstract
Purpose
Hypocitraturia is cited as one of the risk factors promoting stone formation or recurrence of nephrolithiasis. We estimated the relationship between hypocitraturia and other metabolic abnormalities, such as hypercalciuria, hyperuricosuria and hyperoxaluria. The effects of potassium citrate medication were also investigated.
Materials and Methods
We selected 706 renal stone patients with hypocitraturia (<320mg/day), who had received extracorporeal shock wave lithotripsy (ESWL) treatment, and examined the relationship between hypocitraturia and other metabolic abnormalities according to sex and age. We also examined the increment effect of urinary citrate and stone-free rate following potassium citrate (Urocitra®) medication.
Results
Complicated hypocitraturia (coexistence with other metabolic abnormalities) was found in 332 of the 706 patients (47.0%). Of the 706 patients, 242 (34.3%), 112 (15.9%) and 33 (4.7%) had hyperoxaluria, hyperuricosuria and hypercalciuria, respectively. Complicated hypocitraturia was higher in the male than female subjects, and was statistically significant (50.4% vs. 39.8%). In 287 (77%) of the 373 patients who received potassium citrate treatment, the urinary citrate level was increased. The mean urinary citrate level was significantly increased (142.5 vs. 336.2 mg/day) (p<0.01), but the stone free rate was not following the citrate treatment.
References
1. Menon M, Resnick MI. Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Urinary lithiasis: etiology, diagnosis, and medical management. Campbell's urology. 2002. 8th ed. Philadelphia: Saunders;3229–3305.
2. Begun FP, Foley WD, Peterson A, White B. Patient evaluation. Laboratory and imaging studies. Urol Clin North Am. 1997. 24:97–116.
3. Pak CY. Citrate and renal calculi. Miner Electrolyte Metab. 1987. 13:257–266.
4. Tiselius HG, Berg C, Fornander AM, Nilsson MA. Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc. 1993. 7:381–390.
5. Hess B, Zipperle L, Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol. 1993. 265:F784–F791.
6. Welshman SG, McGeown MG. Urinary citrate excretion in stone-formers and normal controls. Br J Urol. 1976. 48:7–11.
7. Bell NH, Stern PH, Pantzer E, Sinha TK, DeLuca HF. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest. 1979. 64:218–225.
8. Yagisawa T, Hayashi T, Yoshida A, Kobayashi C, Okuda H, Ishikawa N, et al. Comparison of metabolic risk factors in patients with recurrent urolithiasis stratified according to age and gender. Eur Urol. 2000. 38:297–301.
9. Pak CY, Fuller CJ, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985. 134:11–19.
10. Pak CY, Britton F, Peterson R, Ward D, Northcutt C, Breslau NA, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med. 1980. 69:19–30.
11. Matsushita K, Tanikawa K, Masuda A, Matsuzaki S. Clinical significance of hypocitraturia in kidney stone patients. Nippon Jinzo Gakkai Shi. 1993. 35:1253–1257.
12. Serra A, Domingos F, Salgueiro C, Prata MM. Metabolic evaluation of recurrent idiopathic calcium stone disease in Portugal. Acta Med Port. 2004. 17:27–34.
13. Nicar MJ, Skurla C, Sakhaee K, Pak CY. Low urinary citrate excretion in nephrolithiasis. Urology. 1983. 21:8–14.
14. Schwille PO, Scholz D, Paulus M, Engelhardt W, Sigel A. Citrate in daily and fasting urine: results of controls, patients with recurrent idiopathic calcium urolithilasis, and primary hyperparathyroidism. Invest Urol. 1979. 16:457–462.
15. Rudman D, Dedonis JL, Fountain MT, Chandler JB, Gerron GG, Fleming GA, et al. Hypocitraturia in patients with gastrointestinal malabsorption. N Engl J Med. 1980. 303:657–661.
16. Hodgkinson A. Citric acid excretion in normal adults and in patients with renal calculus. Clin Sci. 1962. 23:203–212.
17. Hong JW, Choi SH. Excretion of urinary citric acid in stone patients. Korean J Urol. 1992. 33:837–840.
18. Hess B, Hasler-Strub U, Ackermann D, Jaeger P. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant. 1997. 12:1362–1368.
19. Baggio B, Gambaro G. Abnormal arachidonic acid content of membrane phospholipids - the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Nephrol Dial Transplant. 1999. 14:553–555.
20. Pak CY, Sakhaee K, Fuller CJ. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Trans Assoc Am Physicians. 1983. 96:294–305.
21. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997. 158:2069–2073.
22. Jeong YB, Kim YG, Hwang TK, Kim DS, Lee JZ, Kim HH, et al. The physiologic effects of the Urocitra® in patients with urolithiasis. Korean J Urol. 2002. 43:468–473.
23. Yoon SH, Moon YT. Biochemical effect of dietary natural fruit juice in the patients with hypocitraturic calcium urolithiasis. Korean J Urol. 1999. 40:677–682.
24. Park NJ, Kim TK. Change of 24-hour urinary citrate level after dietary manipulation with lemon juice in urolithiasis patients. Korean J Urol. 1999. 40:147–151.
XML Download